Amgen Inc.

AMGNleader

Amgen is one of the world's largest biotechnology companies, pioneering the development of biologic medicines since the 1980s. Its acquisition of Horizon Therapeutics strengthened its rare disease portfolio, while MariTide, its obesity drug candidate, represents a potential blockbuster entry into the weight-loss market.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($33.4B)

静态数据（加载实时财务…）

General Medicine (Prolia, Repatha, Evenity) (35%)

Inflammation (Enbrel, Otezla) (20%)

Oncology/Hematology (25%)

Horizon Therapeutics Portfolio (20%)

业务板块构成与主要客户

产品详情

Repatha/Prolia/Xgeva30%

PCSK9 inhibitor for cholesterol and bone-targeting antibodies for osteoporosis/cancer

Enbrel20%

Anti-TNF biologic for rheumatoid arthritis and psoriasis

Tezspire/Lumakras25%

Next-gen asthma biologic and first KRAS inhibitor for lung cancer

供应链关系

竞争对手

AbbVie Inc.

Immunology biologics (Enbrel vs Humira)

影响: Long-standing rivalry

Eli Lilly and Company

Obesity and cardiometabolic drugs

影响: Emerging obesity competition

Pfizer Inc.

Biosimilars and inflammation

影响: Broad pharma competition

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 Amgen Inc. 的 AI 供应链分析。

企业信息

总部

Thousand Oaks, California, USA

成立时间

1980

员工人数

27,000+

官网

amgen.com

行业概况 — 제약 / 바이오

行业新闻